| €29m research grant to assess risk posed by deadly lung infections. Led by Professor Harish Nair at the University of Edinburgh (ReSViNET board member), the RSV Consortium in Europe (RESCEU) – aims to make a fundamental difference to the understanding and management of RSV. RESCEU was born out of an existing research collaboration called the Respiratory Syncytial Virus Network (ReSViNET) |  |
|
0 Comments
There has been much attention on the news about the outbreak of the RS virus in the Netherland, which is endangering lives of many babies. Children’s hospitals and their intensive care units are overcrowded at the moment. The children's ICs are faced with a massive influx of patients due to the outbreak. For this reason, children were even forced to be treated in hospitals abroad  The virus is characterized by being "a frequent guest around Christmas". During this period the IC units for children are full with babies suffering from pneumonia by the RS virus. Especially for children under the age of 2 years, the virus can be quite stressful. They experience difficulty breathing, shortness of breath, diarrhoea and vomiting. For children under the age of three months, the virus can be life-threatening. Louis Bont, charmain of ReSViNET was interviewed by the Dutch news channel RTL about the current outbreak in the Netherlands.
To this date, no vaccine against this virus had been developed. We are all working very hard to change that. This outbreak shows the importantance of the ReSViNET and its collaboration with various pharmaceutical companies, policy makers, physicians and researchers all around the world We are delighted to inform you that the report of our successful ReSViNET meeting in Zeist (2-3 March 2016) is published in “Journal of Global Health”. We invite you to read the full report by downloading the file via the link below.  
 We are very proud to announce that our board member, Dr. Federico Martinón Torres and his team, designed a new clinical scale for infants with acute respiratory infection, the ReSVinet scale. Our scale is based on seven parameters (feeding intolerance, medical intervention, respiratory difficulty, respiratory frequency, apnoea, general condition, fever) that were assigned different values (from 0 to 3) for a total of 20 points. 170 children under two years of age with ARI were assessed independently by three pediatricians using this scale.
We invite you to read the full report by downloading the file via the link below
We would like to present a summary of the expert meeting by means of a short video. The video provides an impression of the presentations and the ambiance of the day. We sincerely hope you have enjoyed your stay, or will be encouraged to join us next time!
Figures 3A,B and C from our article published in Lancet Respiratory Medicine.We are proud to announce that Lancet Respiratory Medicine has published our article titled:
"LOWER RESPIRAROTY TRACT INFECTION CAUSED BY RESPIRATORY SYNCYTIAL VIRUS: CURRENT MANAGEMENT AND NEW THERAPEUTICS". It is our pleasure to invite you to visit The Lancet website using the following link: http://www.thelancet.com/journals/lanres/onlinefirst Please contact ReSViNET network manager Leyla Kragten-Tabatabaie (leyla.kragten@resvinet.org) if you would like to receive the full article as a .pdf document. ReSViNET and Julius Clinical will attend the 33th annual meeting of the ESPID, from 16-20 May, which will take place in Leipzig, Germany. The European Society for Paediatric Infectious Diseases (ESPID) is a non-profit medical association that focuses on paediatric infectious diseases (PID). Professor Louis Bont, chairman of ReSViNET will be happy to meet you. Of course it's also possible to schedule a meeting in advance. Contact us: businessdevelopment@juliusclinical.com or info@resvinet.org  |
Categories
All
Archives
January 2017
|
||
RSS Feed
